5-ASA Delivers Deep Objective Remission, But Urgency Persists in UC
This real-world Belgian cohort quantifies how far 5-aminosalicylic acid monotherapy can carry mild-to-moderate ulcerative colitis patients toward modern treat-to-target endpoints and where it falls short.
📅 Journal publication: Aug 5, 2026·Last updated: Aug 13, 2026
5-ASA shows strong remission rates but struggles with deep remission in UC.
This study evaluates the real-world effectiveness of 5-aminosalicylic acid (5-ASA) in achieving clinical goals in patients with ulcerative colitis (UC). High rates of biological (78%), endoscopic (87%), and histological (80%) remission were observed, but deep remission was only 24% due to persistent urgency. The results confirm 5-ASA's relevance in mild-to-moderate UC and emphasize the need to manage residual symptoms despite mucosal healing. 5-ASA effectively induces remission but residual symptoms remain a challenge.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Reenaers C, Lambrecht G, Pouillon L, Baert F, Cremer A, Colard A, Claessens C, Billiet T, Geldof J, De Zutter A, Rahier JF, Somers M, Reynders D, Vansteenkiste L, Arijs I, Louis E, Belgian IBD Research and Development Group (BIRD), Verstockt B
Citation:Reenaers C, Lambrecht G, Pouillon L, et al. Characterization of remission levels in patients with ulcerative colitis treated with 5-aminosalicylates: results of the cross-sectional CARUC-ASA study by the Belgian IBD Research and Development Group. Journal of Crohn's & colitis. 2026;20(8). doi:10.1093/ecco-jcc/jjag100